Form 10-Q XOMA Corp For: Mar 31

Related Keywords

United States ,Delaware ,San Francisco Bay ,California ,Ukraine ,Washington ,Emeryville ,American ,America ,Incyte Europe ,Bradley Sitko ,Chiesi Farmaceutici ,Denovo Biopharma ,Thomas Burns ,Rowen Hughes ,Jamesr Neal ,Servier ,Sonnet Biotherapeutics Inc ,Centers For Medicare Medicaid Services ,European Medicines Agency ,Us Supreme Court ,Wyeth Pharmaceuticals ,Silvergate Capital Corp ,Rezolute Inc ,Merck Kga ,Novartis ,Company Board Of Directors ,Dyax Corp ,Trademark Office ,Merck Kgaa ,Drug Administration ,Department Of Health ,Hc Wainwright Co ,Corporation Law ,Novartis Institutes For Biomedical Research Inc ,Company License Agreement ,Silicon Valley Bank ,Aptevo Therapeutics Inc ,Checkmate Pharmaceuticals ,Ology Bioservices Inc ,Securities Exchange ,Medexus Pharmaceuticals Inc ,Biotechnology Value Fund ,Novartis International Pharmaceutical Ltd ,Janssen Biotech Inc ,National Resilience Inc ,Astrazeneca ,Nanotherapeutics Inc ,Exchange Commission ,Company Collaboration Agreement ,European Commission ,Deposit Insurance Corporation ,Commission File No ,Health Information Technology ,Organon International Gmb ,Bioasis Technologies Inc ,Diagnostics Inc ,Company Annual Report On Form ,Company Commercial Payment Purchase Agreement ,Chiron Corporation ,Antria Bio Inc ,B Riley Securities Inc ,Pfizer Inc ,Takeda Pharmaceutical Company ,Merck Sharp Dohme Corp ,Signature Bank ,California Department Of Financial Protection ,Affitech Research ,Pfizer ,Federal Reserve ,Clinical Health ,Investment Company ,Human Services ,Company Series ,Kuros Royalty Fund ,International Conference On Harmonization Good Clinical Practices ,Prothena Biosciences ,Regeneron Pharmaceuticals Inc ,Company Royalty Purchase Agreement ,Aronora Inc ,Company To Aronora ,Public Health Service ,Health Insurance Portability ,Oncobiologics Inc ,Health Care ,European Union ,National Institutes Of Health ,Company Payment Interest Purchase Agreement ,Agenus Inc ,Company Ip Acquisition Agreement ,Company Seriesa Preferred Stock ,Viracta Therapeutics Inc ,Molecular Templates Inc ,Zip Code ,Cumulative Perpetual Preferred Stock ,Seriesb Cumulative Perpetual Preferred Stock ,Securities Exchange Act ,Interactive Data File ,Regulations T ,Exchange Act ,Term Incentive ,Stock Award Plan ,Market Issuance Sales Agreement ,Company Act ,Patient Protection ,Affordable Care Act ,Education Reconciliation Act ,Commercial Payment Purchase Agreement ,Royalty Purchase Agreement ,Antibody License ,License Agreement ,Letter Agreement ,Officer Employment Agreement ,Payment Interest Purchase Agreement ,Commercial Payment Purchase ,Financial Instruments ,Riley Securities ,Value Fund ,Consumer Privacy Act ,Good Manufacturing ,Collaboration Agreement ,Stock Purchase Plan ,Corrupt Practices Act ,Accountability Act ,Novartis Institutes ,Biomedical Research ,Novartis Vaccines ,National Resilience ,Severance Plan ,Antria Bio ,Seriesb Preferred ,Preferred Stock ,Seriesb Preferred Stock ,Oxley Act ,Annual Report ,Months Ended March ,Cash Flow Information ,Significant Accounting ,Future Revenue ,Black Scholes Model ,United States Treasury ,Future Milestones ,Current Expected Credit ,Share Attributable ,California Department ,Financial Protection ,Financial Instruments Credit Losses ,Business Combinations ,Contract Assets ,Contact Liabilities ,Consolidated Financial Statements ,Loss Per Share Attributable ,Organon License Agreement ,Organon License ,Antibody License Agreement ,Gevokizumab License Agreement ,Les Laboratories Servier ,Gevokizumab License ,Exclusivity Option ,Servier Loan ,Takeda Collaboration Agreement ,Molecular Templates ,Takeda Collaboration ,Rezolute License ,Royalty Sale Agreement ,Restated License Agreement ,Royalty Sale Agreements ,Acquisition Agreements ,Bioasis Contingent Consideration ,Second Bioasis ,Bayer Product ,Security Agreement ,Bayer Products ,Royalty Milestones ,Aronora Contingent Consideration ,Palo Licensed Products ,Day One Biopharmaceuticals ,Checkmate Pharmaceutical ,Payment Purchase Agreement ,Nasdaq Stock Market ,Aronora Royalty Milestones ,Kuros Sales Milestones ,Affitech Sales Milestones ,Obseva Sales Milestones ,Obseva Non Sales Milestones ,Aptevo Contingent ,Aptevo Contingent Consideration ,American Arbitration ,International Centre ,Dispute Resolution ,Based Compensation ,Stock Options ,Executive Chairman ,Chief Investment Officer ,Option Inducement ,Stock Option Inducement Awards ,Nasdaq Listing Rule ,Amended Retention Plan ,Initial Period ,Restated Employment Agreement ,Departure Date ,Continuity Incentive ,Seriesb Depositary ,Securities Act ,Seriesb Depositary Shares ,President Biden ,Inflation Reduction Act ,Inflation Act ,Quarterly Report ,Private Securities Litigation Reform Act ,Commercial Payment Purchase Agreements ,Condensed Consolidated Financial ,Condensed Consolidated Financial Statements ,Milestone Payments ,Interim Chief Executive Officer ,Principal Executive Officer ,Chief Financial Officer ,Investment Company Act ,Royalty Aggregator ,Financial Results ,Silvergate Capital ,Federal Food ,Cosmetic Act ,International Conference ,Harmonization Good Clinical Practices ,European Clinical Trials Directive ,America Invents Act ,Good Manufacturing Practice ,Data Integrity ,San Francisco Bay Area ,Budget Control Act ,American Taxpayer Relief Act ,American Economy ,Comprehensive Plan ,Addressing High Drug Prices ,Medicaid Innovation ,Medicaid Services ,Anti Kickback Statute ,False Claims Act ,Clinical Health Act ,Trade Control ,Nasdaq Marketplace Rule ,Delaware General Corporation Law ,Revenue Code ,Tax Act ,Interim Chief Executive ,Vice President ,Principal Financial ,Principal Accounting Officer ,